Citations (122)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (24)
Yingnan Zhao, Yanping Li, Qinhui Liu, Qin Tang, Zijing Zhang, Jinhang Zhang, Cuiyuan Huang, Hui Huang, Guorong Zhang, Jian Zhou, Jiamin Yan, Yan Xia, Zhiyong Zhang & Jinhan He. (2021) Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway. Drug Design, Development and Therapy 15, pages 2117-2128.
Read now
Read now
Maka Siamashvili & Stephen N. Davis. (2021) Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Expert Opinion on Pharmacotherapy 22:16, pages 2181-2198.
Read now
Read now
Haroon Jakher, Tara I Chang, Marilyn Tan & Kenneth W Mahaffey. (2019) Canagliflozin review – safety and efficacy profile in patients with T2DM. Diabetes, Metabolic Syndrome and Obesity 12, pages 209-215.
Read now
Read now
Jaime A Davidson. (2019) SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgraduate Medicine 131:4, pages 251-260.
Read now
Read now
Katherine Merton, Michael J. Davies, Ujjwala Vijapurkar, Doreen Inman & Gary Meininger. (2018) Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. Current Medical Research and Opinion 34:2, pages 313-318.
Read now
Read now
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis & Vasilios G. Athyros. (2017) The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology 10:11, pages 1251-1261.
Read now
Read now
Nicole M Gerlanc, Jennifer Cai, Joseph Tkacz, Susan C Bolge & Brenna L Brady. (2017) The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin. Diabetes, Metabolic Syndrome and Obesity 10, pages 89-99.
Read now
Read now
Michael J Davies, Katherine W Merton, Ujjwala Vijapurkar, Dainius A Balis & Mehul Desai. (2017) Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes, Metabolic Syndrome and Obesity 10, pages 47-55.
Read now
Read now
Awadhesh Kumar Singh & Ritu Singh. (2017) Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Expert Review of Clinical Pharmacology 10:6, pages 633-647.
Read now
Read now
Rong Qiu, Dainius Balis, John Xie, Michael J. Davies, Mehul Desai & Gary Meininger. (2017) Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion 33:3, pages 553-562.
Read now
Read now
Guntram Schernthaner, Fernando J. Lavalle-González, Jaime A. Davidson, Holly Jodon, Ujjwala Vijapurkar, Rong Qiu & William Canovatchel. (2016) Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Postgraduate Medicine 128:8, pages 725-730.
Read now
Read now
Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi & Ichiro Nakamura. (2016) Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opinion on Pharmacotherapy 17:15, pages 1985-1994.
Read now
Read now
Lawrence Blonde, Kaj Stenlöf, Albert Fung, John Xie, William Canovatchel & Gary Meininger. (2016) Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine 128:4, pages 371-380.
Read now
Read now
Matthew R. Weir. (2016) The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgraduate Medicine 128:3, pages 290-298.
Read now
Read now
Fernando J. Lavalle-González, Freddy G. Eliaschewitz, Sonia Cerdas, Maria Del Pilar Chacon, Cindy Tong & Maria Alba. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research and Opinion 32:3, pages 427-439.
Read now
Read now
Rizwana Parveen, Nidhi Bharal Agarwal, Neelam Kaushal, Ghanshyam Mali & Sheikh Raisuddin. (2016) Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opinion on Pharmacotherapy 17:1, pages 105-115.
Read now
Read now
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar & Gary Meininger. (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion 31:12, pages 2219-2231.
Read now
Read now
Jochen Seufert. (2015) SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity 8, pages 543-554.
Read now
Read now
Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel & Gary Meininger. (2015) Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion 31:11, pages 1993-2000.
Read now
Read now
Michael A Nauck. (2014) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy 8, pages 1380-1380.
Read now
Read now
Rosemarie Lajara. (2014) The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 15:17, pages 2565-2585.
Read now
Read now
Jaime A. Davidson & Louis Kuritzky. (2014) Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine 126:6, pages 33-48.
Read now
Read now
Stephen Brunton & Timothy S. Reid. (2014) Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice 42:3, pages 96-108.
Read now
Read now
Shana Traina, Robert Guthrie & April Slee. (2014) The Impact of Weight Loss on Weight-related Quality of Life and Health Satisfaction: Results From a Trial Comparing Canagliflozin With Sitagliptin in Triple Therapy Among People With Type 2 Diabetes. Postgraduate Medicine 126:3, pages 7-15.
Read now
Read now
Articles from other publishers (98)
Lu Chen, Qingxia Xue, Chunyan Yan, Bingying Tang, Lu Wang, Bei Zhang & Quan Zhao. (2023) Comparative safety of different recommended doses of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. Frontiers in Endocrinology 14.
Crossref
Crossref
Hang-Long Li, Yi-Kei Tse, Chanchal Chandramouli, Nicole Wing-Lam Hon, Ching-Lung Cheung, Lok-Yee Lam, Meizhen Wu, Jia-Yi Huang, Si-Yeung Yu, Ka-Lam Leung, Yue Fei, Qi Feng, Qingwen Ren, Bernard M Y Cheung, Hung-Fat Tse, Subodh Verma, Carolyn S P Lam & Kai-Hang Yiu. (2022) Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. The Journal of Clinical Endocrinology & Metabolism 107:12, pages 3442-3451.
Crossref
Crossref
Henri Gouraud, Joshua D Wallach, Rémy Boussageon, Joseph S Ross & Florian Naudet. (2022) Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis. BMJ Medicine 1:1, pages e000154.
Crossref
Crossref
Qiang Geng, Fangjie Hou, Yonghuan Zhang, Zhengzhong Wang & Meiling Zhao. (2022) Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis. Journal of Hypertension 40:5, pages 996-1001.
Crossref
Crossref
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Umesh Dashora, Smeeta Sinha, Samuel Seidu, Dipesh C. Patel, Hannah Beba & W. David Strain. (2022) Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy 13:5, pages 889-911.
Crossref
Crossref
Yu Jiang, Pingping Yang, Linghua Fu, Lizhe Sun, Wen Shen & Qinghua Wu. (2022) Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology 13.
Crossref
Crossref
Daria M. Keller, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, Thilini Walgamage, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kałużna-Oleksy, Maciej Lesiak & Ewa Straburzyńska-Migaj. (2022) SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review. Journal of Clinical Medicine 11:6, pages 1470.
Crossref
Crossref
Alexis Sudlow, DimitriJ Pournaras & CarelW le Roux. (2022) Combining metabolic surgery with medications for type 2 diabetes: Is there a benefit?. Journal of Bariatric Surgery 0:0, pages 0.
Crossref
Crossref
Jing Xu, Taro Hirai, Daisuke Koya & Munehiro Kitada. (2021) Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. Journal of Clinical Medicine 11:1, pages 137.
Crossref
Crossref
Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li & Fei Xie. (2021) SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Public Health 9.
Crossref
Crossref
Ana L. Santos & Sanchari Sinha. (2021) Obesity and aging: Molecular mechanisms and therapeutic approaches. Ageing Research Reviews 67, pages 101268.
Crossref
Crossref
Ashish Sarraju, Gabriela Spencer-Bonilla, Fatima Rodriguez & Kenneth W Mahaffey. (2021) Canagliflozin and cardiovascular outcomes in Type 2 diabetes. Future Cardiology 17:1, pages 39-48.
Crossref
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis & Pantelis Sarafidis. (2020) The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry 27:39, pages 6682-6702.
Crossref
Crossref
Adriana Sánchez-García, Mario Simental-Mendía, Juan Manuel Millán-Alanís & Luis E. Simental-Mendía. (2020) Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacological Research 160, pages 105068.
Crossref
Crossref
Margery A. Connelly, Jonathan Velez Rivera, John R. Guyton, Mohammad Shadab Siddiqui & Arun J. Sanyal. (2020) Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 52:4, pages 619-636.
Crossref
Crossref
Xiaodan Zhang, Zhen Zhong, Yanli Li & Wangen Li. (2020) Long‐term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews 36:5.
Crossref
Crossref
Kazuomi Kario, Keith C. Ferdinand & James H. O'Keefe. (2020) Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progress in Cardiovascular Diseases 63:3, pages 249-262.
Crossref
Crossref
Harold E. Bays, Plamen Kozlovski, Qing Shao, Pieter Proot & Deborah Keefe. (2020) Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Obesity 28:5, pages 870-881.
Crossref
Crossref
Ping Wu, Zhenyu Liu, Xiaohong Jiang & Hao Fang. (2020) An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes. Current Drug Targets 21:5, pages 445-457.
Crossref
Crossref
Aihua Wang, Keming Yang, Tiansheng Wang, Ning Zhang, Huilin Tang & Xin Feng. (2019) Effects of sodium‐glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews 36:1.
Crossref
Crossref
Salvatore Carbone & Dave L. Dixon. (2019) The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Iliana C. Lega, Susan E. Bronskill, Michael A. Campitelli, Jun Guan, Nathan M. Stall, Kenneth Lam, Lisa M. McCarthy, Andrea Gruneir & Paula A. Rochon. (2019) Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes. Diabetes, Obesity and Metabolism 21:11, pages 2394-2404.
Crossref
Crossref
Konstantinos Imprialos, Konstantinos Stavropoulos & Vasilios Papademetriou. (2019) Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics 15:4, pages 519-530.
Crossref
Crossref
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn & Nam Hoon Kim. (2019) Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Scientific Reports 9:1.
Crossref
Crossref
Angus Gill, Stephen P. Gray, Karin A. Jandeleit-Dahm & Anna M.D. Watson. (2019) SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. Current Diabetes Reviews 15:5, pages 349-356.
Crossref
Crossref
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou & Nikolaos Tentolouris. (2019) SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health 16:16, pages 2965.
Crossref
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis & Pantelis Sarafidis. (2019) The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry 11:11, pages 1285-1303.
Crossref
Crossref
Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao & Beiyan Bao. (2019) Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. International Urology and Nephrology 51:4, pages 655-669.
Crossref
Crossref
Hongmei Wang, Jiadan Yang, Xi Chen, Feng Qiu & Juan Li. (2019) Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis. Clinical Therapeutics 41:2, pages 322-334.e11.
Crossref
Crossref
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang & Jun Liang. (2019) Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. Medicine 98:49, pages e18245.
Crossref
Crossref
Zh. D. Kobalava & G. К. Kiyakbaev. (2018) TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY?. Russian Journal of Cardiology:8, pages 79-91.
Crossref
Crossref
H. Sims, K. H. Smith, P. Bramlage & J. Minguet. (2018) Sotagliflozin: a dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus. Diabetic Medicine 35:8, pages 1037-1048.
Crossref
Crossref
William V Tamborlane, David Polidori, Domenick Argenti & Nicholas A Di Prospero. (2018) Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 19:4, pages 649-655.
Crossref
Crossref
Sei Higuchi, M. Concepción Izquierdo & Rebecca A. Haeusler. (2018) Unexplained reciprocal regulation of diabetes and lipoproteins. Current Opinion in Lipidology 29:3, pages 186-193.
Crossref
Crossref
Jaime Davidson, Sanjay Kalra, Vikram Singh, Mayuresh Fegade, Gursimran Singh & Amey Mane. (2017) Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S159-S168.
Crossref
Crossref
Mohamed Hassanein, Akram Echtay, Ahmed Hassoun, Monira Alarouj, Bachar Afandi, Raffi Poladian, Abdullah Bennakhi, Maciej Nazar, Paul Bergmans, Sofia Keim, Gill Hamilton & Sami T. Azar. (2017) Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). International Journal of Clinical Practice 71:10, pages e12991.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
Darin Ruanpeng, Patompong Ungprasert, Jutarat Sangtian & Tasma Harindhanavudhi. (2017) Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes/Metabolism Research and Reviews 33:6, pages e2903.
Crossref
Crossref
Niki Katsiki, Nikolaos Tentolouris & Dimitri P. Mikhailidis. (2017) Dyslipidaemia in type 2 diabetes mellitus. Current Opinion in Cardiology 32:4, pages 422-429.
Crossref
Crossref
June Felice Johnson, Rahul Parsa & Robert A. Bailey. (2017) Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA 1c and Age. Clinical Therapeutics 39:6, pages 1123-1131.
Crossref
Crossref
Lee Ling Lim, Alexander Tong Boon Tan, Kevin Moses, Viraj Rajadhyaksha & Siew Pheng Chan. (2017) Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. Journal of Diabetes and its Complications 31:2, pages 494-503.
Crossref
Crossref
Jennifer L. Sherr, Eda Cengiz, Michelle A. Van Name, Stuart A. Weinzimer & William V. Tamborlane. 2017. Textbook of Diabetes. Textbook of Diabetes
985
999
.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt & Norman Waugh. (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment 21:2, pages 1-218.
Crossref
Crossref
Ralph A. DeFronzo, Luke Norton & Muhammad Abdul-Ghani. (2016) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology 13:1, pages 11-26.
Crossref
Crossref
Matteo Monami, Ilaria Dicembrini & Edoardo Mannucci. (2016) Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetologica 54:1, pages 19-36.
Crossref
Crossref
Miles Fisher & Gerard McKayMiles Fisher. 2017. Essentials of SGLT2 Inhibitors in Diabetes. Essentials of SGLT2 Inhibitors in Diabetes
51
68
.
Nina A. Petunina, Anna L. Terekhova & Ekaterina V. Goncharova. (2016) Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor. Diabetes mellitus 19:6, pages 511-517.
Crossref
Crossref
Anna Solini. (2016) Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Acta Diabetologica 53:6, pages 863-870.
Crossref
Crossref
Heidi Storgaard, Lise L. Gluud, Cathy Bennett, Magnus F. Grøndahl, Mikkel B. Christensen, Filip K. Knop & Tina Vilsbøll. (2016) Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLOS ONE 11:11, pages e0166125.
Crossref
Crossref
David Polidori, Arjun Sanghvi, Randy J. SeeleyKevin D. Hall. (2016) How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. Obesity 24:11, pages 2289-2295.
Crossref
Crossref
Mathew John, Sonia Cerdas, Rafael Violante, Chaicharn Deerochanawong, Mohamed Hassanein, April Slee, William Canovatchel & Gill Hamilton. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice 70:9, pages 775-785.
Crossref
Crossref
Luc Van Gaal & Eveline Dirinck. (2016) Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. Diabetes Care 39:Supplement_2, pages S260-S267.
Crossref
Crossref
H. W. Rodbard, J. Seufert, N. Aggarwal, A. Cao, A. Fung, M. Pfeifer & M. Alba. (2016) Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes, Obesity and Metabolism 18:8, pages 812-819.
Crossref
Crossref
Richard E. Gilbert, Matthew R. Weir, Paola Fioretto, Gordon Law, Mehul Desai, Irina Kline, Wayne Shaw & Gary Meininger. (2016) Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes 40:3, pages 247-257.
Crossref
Crossref
Alena Adamíková. (2016) Canagliflozin-inhibitor SGLT2 in diabetes mellitus therapy. Interní medicína pro praxi 18:2, pages 103-106.
Crossref
Crossref
Belén Dalama, Betina Biagetti & Jordi Mesa. (2016) Eliminación renal de glucosa como tratamiento de la diabetes: de un antiguo método diagnóstico a una nueva forma de tratamiento. Medicina Clínica 146:10, pages 460-464.
Crossref
Crossref
Belén Dalama, Betina Biagetti & Jordi Mesa. (2016) Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment. Medicina Clínica (English Edition) 146:10, pages 460-464.
Crossref
Crossref
H. Drexel & C. H. Säly. (2016) Kardiovaskuläre Effekte von SGLT-2-HemmernCardiovascular effects of SGLT2 inhibitors. Der Diabetologe 12:3, pages 195-200.
Crossref
Crossref
Hui WangXiufei LiuMin LongYi HuangLinlin ZhangRui ZhangYi ZhengXiaoyu LiaoYuren WangQian LiaoWenjie LiZili TangQiang TongXiaocui WangFang FangMontserrat Rojo de la VegaQin OuyangDonna D. ZhangShicang YuHongting Zheng. (2016) NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine 8:334.
Crossref
Crossref
Eva Y Wong. (2016) A Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus. Pharmacy & Pharmacology International Journal 4:2.
Crossref
Crossref
Julio Rosenstock, Leonard Chuck, Manuel González-Ortiz, Kate Merton, Jagriti Craig, George Capuano & Rong Qiu. (2016) Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. Diabetes Care 39:3, pages 353-362.
Crossref
Crossref
Alan J. Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Wayne Shaw, Mehul Desai & Gary Meininger. (2016) Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society 64:3, pages 543-552.
Crossref
Crossref
L.A. Leiter, T. Forst, D. Polidori, D.A. Balis, J. Xie & S. Sha. (2016) Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes & Metabolism 42:1, pages 25-32.
Crossref
Crossref
G. Fulcher, D. R. Matthews, V. Perkovic, D. de Zeeuw, K. W. Mahaffey, C. Mathieu, V. Woo, C. Wysham, G. Capuano, M. Desai, W. Shaw, F. Vercruysse, G. Meininger & B. Neal. (2016) Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 18:1, pages 82-91.
Crossref
Crossref
Grabner Michael, Peng Xiaomei, Caroline Geremakis & Jay Bae. (2015) Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. Journal of Managed Care & Specialty Pharmacy 21:12, pages 1204-1212.
Crossref
Crossref
Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans J. Woerle & Uli C. Broedl. (2015) Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Muhammad A. Abdul-Ghani, Luke Norton & Ralph A. DeFronzo. (2015) Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. American Journal of Physiology-Renal Physiology 309:11, pages F889-F900.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Pierre Johansen, Michael Willis, Atanacio Valencia-Mendoza & Andrea Puig. (2015) Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues 8, pages 8-19.
Crossref
Crossref
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
Konstantinos P. Imprialos, Pantelis A. Sarafidis & Asterios I. Karagiannis. (2015) Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. Journal of Hypertension 33:11, pages 2185-2197.
Crossref
Crossref
S. Ikeda, Y. Takano, O. Cynshi, R. Tanaka, A. D. Christ, V. Boerlin, U. Beyer, A. Beck, C. Ciorciaro, M. Meyer & T. Kadowaki. (2015) A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 17:10, pages 984-993.
Crossref
Crossref
Yehuda Handelsman. (2015) Potential Place of SGLT2 Inhibitors in Treatment Paradigms for type 2 Diabetes Mellitus. Endocrine Practice 21:9, pages 1054-1065.
Crossref
Crossref
Ngozi Erondu, Mehul Desai, Kirk Ways & Gary Meininger. (2015) Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 38:9, pages 1680-1686.
Crossref
Crossref
Greg Fulcher, David R. Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Robert Weiss, Julio Rosenstock, George Capuano, Mehul Desai, Wayne Shaw, Frank Vercruysse, Gary Meininger & Bruce Neal. (2015) Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy 6:3, pages 289-302.
Crossref
Crossref
N. B. Amin, X. Wang, J. R. Mitchell, D. S. Lee, G. Nucci & J. M. Rusnak. (2015) Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes, Obesity and Metabolism 17:8, pages 805-808.
Crossref
Crossref
Christopher S. Kovacs, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans-Juergen Woerle & Uli C. Broedl. (2015) Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics 37:8, pages 1773-1788.e1.
Crossref
Crossref
M. D. Sharma. (2015) Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 17:7, pages 616-621.
Crossref
Crossref
Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Hans Stieltjes, Jay Ariyawansa, Nicholas A. Di Prospero & Paul Rothenberg. (2015) Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clinical Pharmacology in Drug Development 4:4, pages 279-286.
Crossref
Crossref
Luc Van Gaal & André Scheen. (2015) Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. Diabetes Care 38:6, pages 1161-1172.
Crossref
Crossref
Karen Whalen, Shannon Miller & Erin St. Onge. (2015) The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Clinical Therapeutics 37:6, pages 1150-1166.
Crossref
Crossref
Gary Meininger, William Canovatchel, David Polidori & Norm Rosenthal. (2015) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 5:3, pages 183-201.
Crossref
Crossref
John P.H. Wilding, Lawrence Blonde, Lawrence A. Leiter, Sonia Cerdas, Cindy Tong, Jacqueline Yee & Gary Meininger. (2015) Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and its Complications 29:3, pages 438-444.
Crossref
Crossref
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger & David Matthews. (2015) Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care 38:3, pages 403-411.
Crossref
Crossref
S. Sha, D. Polidori, K. Farrell, A. Ghosh, J. Natarajan, N. Vaccaro, J. Pinheiro, P. Rothenberg & L. Plum‐Mörschel. (2015) Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study. Diabetes, Obesity and Metabolism 17:2, pages 188-197.
Crossref
Crossref
Curtis TriplittSusan Cornell. (2015) Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S31526.
Crossref
Crossref
Virginia Valentine & Deborah Hinnen. (2015) Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. Clinical Diabetes 33:1, pages 5-13.
Crossref
Crossref
L. Ji, P. Han, Y. Liu, G. Yang, N. K. Dieu Van, U. Vijapurkar, R. Qiu & G. Meininger. (2015) Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes, Obesity and Metabolism 17:1, pages 23-31.
Crossref
Crossref
Alan Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Cristiana Mayer, Albert Fung, Wayne Shaw, Keith Usiskin, Mehul Desai & Gary Meininger. (2014) Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocrine Disorders 14:1.
Crossref
Crossref
Sanjay Kalra. (2014) Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Therapy 5:2, pages 355-366.
Crossref
Crossref
B Haas, N Eckstein, V Pfeifer, P Mayer & M D S Hass. (2014) Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition & Diabetes 4:11, pages e143-e143.
Crossref
Crossref
S. Sha, D. Polidori, T. Heise, J. Natarajan, K. Farrell, S.-S. Wang, D. Sica, P. Rothenberg & L. Plum-Mörschel. (2014) Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 16:11, pages 1087-1095.
Crossref
Crossref
M. A. Abdul-Ghani & R. A. DeFronzo. (2014) Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. Journal of Internal Medicine 276:4, pages 352-363.
Crossref
Crossref
J.-F. Yale, G. Bakris, B. Cariou, J. Nieto, E. David-Neto, D. Yue, E. Wajs, K. Figueroa, J. Jiang, G. Law, K. Usiskin & G. Meininger. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity and Metabolism 16:10, pages 1016-1027.
Crossref
Crossref
Rong Qiu, George Capuano & Gary Meininger. (2014) Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. Journal of Clinical & Translational Endocrinology 1:2, pages 54-60.
Crossref
Crossref
Theodoros P. Angelopoulos & John Doupis. (2014) Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective. Advances in Therapy 31:6, pages 579-591.
Crossref
Crossref
Damayanthi Devineni, Nicole Vaccaro, David Polidori, Sarah Rusch & Ewa Wajs. (2014) Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants. Clinical Therapeutics 36:5, pages 698-710.
Crossref
Crossref
Greg L. Plosker. (2014) Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:7, pages 807-824.
Crossref
Crossref
Hala Yamout, Vlado Perkovic, Melanie Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger & George Bakris. (2014) Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology 40:1, pages 64-74.
Crossref
Crossref